Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell malignancy, have dramatically improved. The development of the immunomodulatory drugs …
C Simsek, E Esin, S Yalcin - Journal of oncology, 2019 - Wiley Online Library
Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …
IS Nijhof, NWCJ van de Donk, S Zweegman… - Drugs, 2018 - Springer
Although survival of multiple myeloma patients has at least doubled during recent years, most patients eventually relapse, and treatment at this stage may be particularly complex. At …
P Bhatt, C Kloock, R Comenzo - Current Oncology, 2023 - mdpi.com
Multiple myeloma remains an incurable disease with the usual disease course requiring induction therapy, autologous stem cell transplantation for eligible patients, and long-term …
E Kastritis, E Terpos… - Blood, The Journal of the …, 2022 - ashpublications.org
Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be …
Abstract Whole Body Low Dose CT (WBLDCT) has important advantages as a first-line imaging modality for bone disease assessment in patients with plasma cell disorders and …
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
P Moreau, E Zamagni, MV Mateos - Blood cancer journal, 2019 - nature.com
Over the last years, there has been great progress in the treatment of multiple myeloma with many new agents and combinations having been approved and being now routinely …
From the 1960s to the early 2000s, alkylating agents (eg, melphalan, cyclophosphamide, and bendamustine) remained a key component of standard therapy for newly-diagnosed or …